ANZ SELLS OPES PRIME ACRUX, SOLAGRAN; STARPHARMA'S ROSS DOBINSON OP OVERHANG CLEARED
April 27th 2008 11:23
Thursday April 24, 2008
Daily news on ASX-listed biotechnology companies
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
ANZ, OPES PRIME
The ANZ has sold 10,899 Acrux shares, reducing its holding to 10,357,618 shares or 6.502 percent of the company.
In its substantial shareholder notice the ANZ said it had not sold any of its 124,484,003 Bioprospect shares or 25.6 percent of the company.
The ANZ has not sold any of its 4,250,400 Incitive shares.
The bank sold 34,145 ordinary Solagran shares leaving it with 56,041,727 ordinary shares representing 42.5 percent of the company, but has not sold any of the 10,132,865 partly paid shares or 21.034 percent.
The ANZ has sold sufficient of the 5,409,928 Virax shares (5.04%) it held to reduce its holding below the five percent substantial level.
STARPHARMA
Starpharma says the 2,788,700 shares (1.55%) formerly held by Starpharma director Ross Dobinson had been bought by two institutional investors and director Dr John Raff.
The 10.4 million Acrux shares being sold by the ANZ were originally held by Mr Dobinson who is also the chairman of Acrux.
In a director’s interest 3Y notice to the ASX Mr Dobinson said he had disposed of his entire Starpharma holding.
The notice said the “shares were held as security under a margin loan arrangement with Opes Prime and have now been sold as part of the disposal program referred to in announcements by the ANZ Group”.
Starpharma fell 1.5 cents or 4.35 percent to 33 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 50 |
| Vote |
Add To: 
subscribe to this blog